moderate incomes are at least partially insured through work and many recognize that they would pay a large portion of the bill for a tax financed system that would generate benefits for those less well off." Such voter apathy or fears about perceived costs have created a "perfect storm of inaction" with respect to adoption of a national pharmacare program or pharmaceutical strategy, MacKinnon says.
Most experts reject the notion that the cost of a national pharmacare program has been the primary barrier to its introduction.
Rather, they say, private interests have a vested interest in maintaining the current system of paying for drugs. "Private insurers and pharmaceutical manufacturers make a lot of money under Canada's very expensive multipayer system," says Morgan. Being able to reform our current system and implement a national strategy would be difficult with "opposition from such interests."
That sentiment is shared by Steven Lewis, an adjunct professor of health policy at the University of Calgary in Alberta, who also views provincial economic policies as a barrier.
"Ontario and Quebec are home to most of the drug R & D [research and development] in Canada and these provinces perceive an interest in policies and practices that are sufficiently attractive to pharma to maintain their R & D spending levels," Lewis says.
But Wendy Zatylny, vice president of federal affairs and communications for Canada's Research-Based Pharmaceutical Companies (Rx&D), the national association of drug makers, says costs are not strictly the issue.
Rather, it's how drug costs impact on overall health care costs, she says. Focusing strictly on drug costs "doesn't take into account the other costs savings and efficiencies elsewhere in the healthcare system … where drugs do save costs downstream, where they reduce the need for hospitalization or surgeries."
In national pharmacare programs, like that of New Zealand, which has often been cited as a model for Canada to emulate, there are "certainly decreased costs in the short term. … But it shifted the burden to other parts of the healthcare system" such as emergency room visits and hospitalizations, Zatylny says.
The experts also say that there's no doubt that jurisdictional wrangling has also played a factor in the failure to establish a national pharmacare program.
As Lewis notes, the provinces are responsible for health care delivery and are in charge of health spending, making it "very difficult to implement any truly national health care programs. … So there is a patchwork of pharma programs that among other things creates a barrier to exercising purchasing power." Among the advantages held out for anything like a national pharmacare program is the capacity to negotiate lower prices for bulk purchases. 
